ProductsHealth

Oncology

The rapid increase in the occurrence of cancer in recent years has led to a corresponding growth in the oncology sector. At the same time, innovative oncology drugs continue to be introduced with improvements in R&D and technology. To meet the trend, OE’s oncology division was established in 2001 to market drugs to treat cancer and other diseases resulting from cellular dysfunction and uncontrolled cell growth..

OE’s main oncology product is Navelbine Oral, indicated for the treatment non-small cell lung and metastatic breast cancers.

• Navelbine Oral is a cost-effective regimen that provides the same efficacy as intravenous drugs, with reduced side effects and increased convenience to significantly improve the quality of life of patients.

Other oncology drugs under development or undergoing clinical trials include:

• Loramyc^®
  Loramyc^® is a muco-adhesive buccal tablet providing an innovative delivery system of muconazole and is indicated for the treatment of oropharyngeal candidiases (OPC) in immuno-compromised patients.
• Multikine^®
  Multikine^®, is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is currently being developed as first-line therapy for advanced primary head and neck cancer
• Nanoplatin^®
  Nanoplatin^® is a micellar nanoparticles containing cisplatin derivatives, produced by a coordination bonds of cisplatin to polyamino acid. It is under development for the indication in pancreatic cancer.

OE will continue to introduce patented new products to increase its oncology product pipeline. The company is also committed to developing an integrated customer network and nurturing expert sales personnel in Singapore, Malaysia, Hong Kong and Taiwan.